Introduction
Hispanics are the largest and fastest growing minority group in the United States (1). Both the incidence and prevalence rates of end-stage renal disease (ESRD) in Hispanics are 1.5 times higher than in non-Hispanics (2). Although it is well established that chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease (CVD) and all-cause mortality (3-5), limited data exist regarding the association of CVD and CKD in Hispanics. This is an area of interest because, in the general population, Hispanics appear to have a survival advantage compared with non-Hispanic Caucasians, despite a higher prevalence of cardiovascular risk factors (6). This observation is referred to as the "Hispanic paradox" and has been inconsistently found in CKD patients. In a large group of individuals with stage 3 or 4 CKD enrolled in Kaiser Permanente of Northern California, Hispanic ethnicity was associated with a lower risk of cardiovascular events and death relative to non-Hispanic Caucasians despite experiencing a higher risk of ESRD (7). In contrast, a study of a nationally representative sample of the U.S. population, the third National Health and Nutrition Examination Survey (NHANES III), demonstrated a nonsignificant trend toward higher mortality in Mexican Americans with CKD than non-Hispanic Caucasians (8) . These heterogeneous findings may be due to differences in the populations studied and methodology but underscore the need for further investigation.
We characterize the prevalence of self-reported clinical CVD and measures of subclinical CVD among Hispanics compared with non-Hispanic Caucasians and African Americans enrolled in two prospective observational studies of CKD: the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic CRIC (HCRIC) Studies.
Materials and Methods

Study Design and Participants
We conducted cross-sectional analyses among Hispanic and non-Hispanic participants at enrollment in the CRIC and HCRIC studies. The design, methods, and baseline characteristics of the CRIC study participants have been previously published (9, 10) . Briefly, the CRIC study is a prospective cohort of 3612 individuals (169 Hispanics and 3443 nonHispanics), aged 21 to 74 years, with mild-to-moderate CKD, recruited between May 2003 and March 2007 from seven clinical centers across the United States. HCRIC is a parallel study to the CRIC study that recruited 327 Hispanics from the Chicago area from October 2005 through June 2008, using the same inclusion criteria. Among all Hispanic participants, 69% were Mexican American, 16% were Puerto Rican, and 15% had other Latin American ancestry. We decided to combine all Hispanic participants in our analyses because no significant differences were found in the outcomes of interest between Hispanic subgroups. Protocols for both studies were approved by the Institutional Review Board of the participating centers and are in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants.
Variables and Measurements
Sociodemographic characteristics, and medications were self-reported at entry. Hypertension was defined as systolic BP Ն140 mmHg, diastolic BP Ն90 mmHg, or use of antihypertensive medications. Diabetes was defined as fasting glucose Ն126 mg/dl, random glucose Ն200 mg/dl, or use of insulin or antidiabetic medication. Dyslipidemia was defined as fasting total cholesterol Ն240 mg/dl, lowdensity lipoprotein (LDL) Ն160 mg/dl, high-density lipoprotein (HDL) Ն40 mg/dl, triglycerides Ն200 mg/dl, or use of lipid-lowering medication. Family history of premature coronary heart disease (CHD) was defined as CHD in male first-degree relative Ͻ55 years, or CHD in female first-degree relative Ͻ65 years. History of CVD, including heart failure, peripheral arterial disease (PAD), stroke or CHD (defined as history of myocardial infarction [MI] or prior revascularization), was self-reported on a medical history questionnaire in the participant's language of preference (English or Spanish). Subclinical CVD measures included left ventricular hypertrophy (LVH), coronary artery calcification score (CAC), and ankle-brachial index (ABI). LVH was defined as left ventricular mass index (g/m 2.7 ) by transthoracic echocardiography (TTE) Ͼ50 in males and Ͼ47 in females. CAC was measured in a subcohort of the CRIC study using electron-beam computed tomography (EBCT) or multi-detector computer tomography. The CRIC subcohort was selected as a stratified, weighted random sample of approximately one third of all participants, based on the anticipated distribution within the full cohort. Subcohort participants were assigned to undergo additional, more intensive testing (including iothalamate clearance studies to measure GFR and EBCT). We considered two cut off points for CAC (Ͼ100 and Ͼ400) as consistent with subclinical CVD. TTE and CAC measurements were performed at the 1-year follow-up visit in the CRIC study. In HCRIC, all participants underwent TTE and CAC measurement at entry. GFR was estimated using the four-variable Modification of Diet in Renal Disease (MDRD) equation (11) . Previous MI on electrocardiogram (ECG) was defined as the presence of Major 2 or 3 Minnesota code criteria (12) .
Statistical Analysis
Descriptive statistics were summarized as mean (SD) for continuous variables and frequency (proportion) for categorical variables. If the data distributions were skewed, natural logarithmic transformations were conducted and/or data were presented as median (interquartile intervals). Crude and adjusted (for age, gender, education, and estimated GFR [eGFR]) means for CVD risk factors were compared between racial/ethnic groups using ANOVA and t tests, as appropriate. Prevalence of self-reported clinical and subclinical measures of CVD was compared using chi-squared tests. To determine factors independently associated with clinical and subclinical measures of CVD, we fitted multivariate hierarchical logistic regression models that included (1) crude (unadjusted) measures, (2) demographic measures, and (3) clinical measures (see Table 4 ). These variables were chosen based on bivariate analyses and prior studies (5, [13] [14] [15] [16] [17] [18] . The only variables with Ͼ3% missing values were proteinuria/24 h (6%), income (15%), and health insurance (12%); the latter two were not included in the regression models. To compare Hispanics with non-Hispanic groups, each model was run twice, once with non-Hispanic Caucasians as reference and once with non-Hispanic African Americans as reference. All hypothesis tests were two-sided with alpha level ϭ 0.05. Among 3939 subjects enrolled in CRIC/HCRIC, 154 selfidentified as member of "other" race/ethnicity were excluded from the analyses. We adopted a complete case analysis approach for all analyses (19) ; therefore, the final analytic cohorts varied among the different analyses presented: (1) 353 participants were excluded from the multivariate analysis of self-reported CVD due to missing data for one of the covariates, (2) 1857 participants were excluded from CAC analyses because they did not undergo CAC measurement as specified by study design (9) , (3) 911 participants were excluded from LVH analyses due to missing data for the outcome (689) or covariates (222), and (4) 398 participants were excluded from ABI analyses because of missing data for this outcome (61) or covariates (337). All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC).
Results
Participant Characteristics and Unadjusted Prevalence of Cardiovascular Risk Factors
Among 3785 CRIC/HCRIC participants in our final analytic cohort ( 925 (24) 92 (19) 416 (25) 417 (25) $50,001-$100,000
694 (18) 24 (5) 455 (28) 215 (13) Ͼ$100,000
369 (10) 12 (2) 295 (18) 62 (4) Missing 584 (15) 56 (11) 218 (13) 310 (9 , P ϭ 0.003), and similar prevalence of CAC (Ͼ100). Using an alternative cutoff for CAC (Ͼ400), similar patterns between Hispanics and non-Hispanics were observed (Table 2) .
Stratified Analyses of Clinical and Subclinical Outcomes
Among participants with eGFR Ͻ30 ml/min/1.73 m 2 , Hispanics had significantly lower prevalence of self-reported CVD, CAC Ͼ100, and CAC Ͼ400, as compared with non-Hispanic Caucasians (P Ͻ 0.05; Table 3 ). Differences in high CAC prevalence was less pronounced when compared with non-Hispanic African Americans. Prevalent LVH was significantly higher in Hispanics than nonHispanic Caucasians within every strata of abnormal eGFR (P Ͻ 0.0001; Table 3 ). Thirty-two percent of Hispanics with eGFR Ͻ30 ml/min/1.73 m 2 had CAC Ͼ100, compared with 53% of non-Hispanic Caucasians (P ϭ 0.003) and 46% of non-Hispanic African Americans (P ϭ 0.05; Table 3 ; Figure 1a ).
In stratified analysis by gender, the prevalence of self-reported CHD was significantly lower among Hispanic males (19%) compared with non-Hispanic Caucasian males (30%, P Ͻ 0.001). Among participants with diabetes, the prevalence of CHD was also lower in Hispanics (21%) compared with non-Hispanic Caucasians (33%, P Ͻ 0.001; data not shown). ECG evidence of previous MI was similar across racial/ethnic groups (8% [H], 7% [C], 9% [A]; P Ͼ 0.05). Forty percent of Hispanics with diabetes had CAC Ͼ100, compared with 64% of non-Hispanic Caucasians (P Ͻ 0.0001; Figure 1b) . This difference was not observed in participants without diabetes (data not shown).
Multivariate Analysis of Clinical and Subclinical Outcomes
In fully adjusted logistic regression models, the prevalence odds of LVH were two times higher among Hispanics compared with non-Hispanic Caucasians (95% confidence interval 1.2 to 3.2, P ϭ 0.005) ( Table 4 ). The fully adjusted prevalence odds of CAC Ͼ400 were 2.5 times higher among Hispanics compared with non-Hispanic African Americans (95% confidence interval 1.1 to 5.6, P ϭ 0.03). Adjusted prevalence odds of self-reported clinical CVD, CAC Ͼ100, and ABI Ͻ0.9 were similar across racial/ ethnic groups.
Achievement of Therapeutic Goals for CVD Prevention
Several differences across racial/ethnic groups were found with respect to the unadjusted prevalence of 
Ͻ0.01
Family history of premature CHD Additionally adjusted for all variables listed. CVD, CAC, and ABI models were additionally adjusted for serum phosphate and calcium. Intact PTH (iPTH) was only analyzed in the CAC models.
achievement of guideline-recommended goals for secondary prevention of CVD ( 
Discussion
At the time of enrollment in the CRIC/HCRIC studies, Hispanics with CKD were at significant socioeconomic disadvantage and had a higher prevalence of most traditional and nontraditional CVD risk factors compared with non-Hispanics, even after accounting for differences in kidney function. However, Hispanics generally had a lower prevalence of most self-reported and subclinical measures of CVD, with the exception of LVH, which was exceptionally common among Hispanics. Furthermore, Hispanics with self-reported CVD were less likely to achieve therapeutic goals for secondary prevention of CVD, including regular exercise, BP, and glycemic control. To our knowledge, our study is the first systematic evaluation of the clinical epidemiology of CVD in Hispanics with CKD across a wide range of age and in comparison with other racial/ethnic groups.
Similar to our findings, in a general population sample from NHANES III, the prevalence of self-reported CHD was lower in Mexican Americans despite the higher prevalence of diabetes, hypertension, and physical inactivity compared with non-Hispanic Caucasians (22) . Possible explanations for these disparities between Hispanics and non-Hispanics include biologic or genetic differences, and cultural variation in disease self-report. In addition, limited access to medical care might decrease the possibility of being diagnosed with a mild cardiovascular event.
Nearly two thirds of Hispanics with CKD had poorly controlled hypertension (BP Ͼ130/80 mmHG), a rate which was almost twofold higher than that observed in non-Hispanic Caucasians in our cohort. Similarly, within NHANES III, Mexican Americans had the highest rate of uncontrolled hypertension (23) . In addition to poorly achieved recommended BP goals, Hispanics were less likely to achieve many other recommended goals for secondary prevention of CVD. The generally poor rates of use of these preventive measures may be related to lack of access to medical care, as evidenced by lack of health insurance in 23% of Hispanics and late or no referral for nephrology care, ineffective patient-provider communication, factors associated with acculturation, and low adherence to medication and medical advice (24) .
We observed a significantly higher prevalence of LVH among Hispanics compared with non-Hispanic Caucasians, as the adjusted prevalence was nearly twice that in the former compared with the latter group. Given the known relationship between hypertension and LVH, this finding is likely best attributed to the higher rates of poor BP control among Hispanics (25, 26) . Other factors that may explain this increased risk include higher body mass index and lower hemoglobin observed in Hispanics compared with non-Hispanic Caucasians (16) . Our findings are consistent with prior studies of non-CKD populations in which Hispanics have been found to have higher prevalence of LVH compared with non-Hispanics (27) (28) (29) . In the Multi-Ethnic Study of Atherosclerosis (MESA), Hispanics were similarly almost twice as likely as non-Hispanic Caucasians to have LVH after adjustment for hypertension and other covariates (28) . These results have clinical relevance because LVH is known to be an independent predictor of cardiovascular morbidity and mortality, and, therefore, more aggressive BP control among Hispanics could contribute to reducing LVH among this group (25, 30) .
We considered two cut-off points for CAC (Ͼ100 and Ͼ400) as consistent with subclinical CVD based on prior (37) . It has been reported previously that the prevalence of peripheral arterial disease in the general population is higher among African Americans than Hispanics (13, 39, 40) . Our study is the first to report the prevalence of measured peripheral arterial disease in a cohort of Hispanics with CKD not yet on dialysis. Similar to prior studies in patients without CKD, we found that Hispanics had lower prevalence of abnormal ABI than non-Hispanic African Americans, which was not present in adjusted analyses and appeared to be explained by differences in sociodemographic factors.
Our study has limitations. First, the majority of Hispanics were recruited at a single center and, therefore, findings may not be generalizable to all U.S. Hispanics. However, the composition of the HCRIC cohort is reflective of the heterogeneity of the U.S. Hispanic population in terms of country of origin and education (1,8,41) . Moreover, the socioeconomic disadvantages observed in HCRIC are similar to those found in Hispanics with CKD in a recent NHANES III analysis (8) . Also, findings from our cohorts may not be generalizable to all types to kidney disease, such as glomerulonephritis. However, the CRIC study is representative of the ESRD population in which diabetes and hypertension are the primary diagnosis for over 70% of patients (10) . Second, clinical CVD was ascertained by self-report of prior history of MI or coronary revascularization, which might be influenced by recall bias. However, this methodology is commonly used in clinical research, and the excellent or substantial agreement between self-reported CHD and the medical record has been previously demonstrated in patients with ESRD (42) . Third, we estimated GFR using the MDRD formula, which has not been validated in Hispanics; however, this formula has been used in other studies of Hispanics with CKD (8, 43) .
Hispanics in CRIC and HCRIC had worse BP control and a higher prevalence of LVH compared with non-Hispanic Caucasians. Moreover, Hispanics with CKD had the lowest rate of achievement of CVD therapeutic targets. The health disparities found in our study are likely the result of a complex interplay among multiple factors at the individual and community levels, the health care system, and society as a whole. The long-term impact of our findings on renal and cardiovascular outcomes will be evaluated in subsequent longitudinal analyses. Future research should be dedicated to examine etiologic factors that may explain our findings.
